De-escalation strategies in differentiated thyroid cancer
Bull Cancer. 2021 Oct 11:S0007-4551(21)00367-2. doi: 10.1016/j.bulcan.2021.07.008. Online ahead of print.ABSTRACTThyroid cancer runs the gamut from indolent micropapillary carcinoma to highly aggressive metastatic disease. Today, using prognostic algorithms, treatment and follow-up can be tailored to each patient in order to decrease overtreatment and over-medicalization of indolent disease. Active surveillance of papillary thyroid carcinoma less than 1cm avoids surgery and thyroid hormone replacement in a large proportion of patient whose tumors remain stable for years. Total thyroidectomy, once a dogma in the treatment o...
Source: Bulletin du Cancer - October 15, 2021 Category: Cancer & Oncology Authors: Dana M Hartl Julien Hadoux Camilo Garcia Abir Al Ghuzlan Joanne Guerlain Ingrid Breuskin Eric Baudin Livia Lamartina Source Type: research

Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health
Bull Cancer. 2021 Oct 7:S0007-4551(21)00308-8. doi: 10.1016/j.bulcan.2021.09.001. Online ahead of print.ABSTRACTSince 2013, the process of pricing of innovative drugs by the French National Health Insurance has considered both cost-effectiveness and budget impact. CAR-T cell therapies were first subject to economic evaluation from 2019 in France. We aim to describe the process and results of the economic evaluation of tisagenlecleucel and axicabtagene ciloleucel as well as the challenges these evaluations raised. Evaluations submitted by the firms were reviewed by HAS and submitted to the Committee of Economic Evaluation a...
Source: Bulletin du Cancer - October 11, 2021 Category: Cancer & Oncology Authors: V éronique Raimond Emmanuelle Kaltenbach Christophe Adam S ébastien Lazzarotto Catherine Le Gal ès Lionel Perrier J érôme Wittwer Source Type: research

Surgical de-escalation in gynecologic oncology
Bull Cancer. 2021 Oct 7:S0007-4551(21)00358-1. doi: 10.1016/j.bulcan.2021.06.012. Online ahead of print.ABSTRACTThe evolution of knowledge in gynecologic oncology is leading to surgical de-escalation in several areas, particularly in lymph node staging. Sentinel lymph node biopsy that was initially used in low and intermediate risk endometrial cancer, has now been extended to high-intermediate and high-risk endometrial cancer. Sentinel lymph node biopsy plays also an important role in the nodal staging of early-stage cervical cancer. The radicality of hysterectomies in patients with early cervical cancer is under debate. S...
Source: Bulletin du Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Fran çois Zaccarini Claire Sanson Amandine Maulard St éphanie Scherier Patricia Pautier Alexandra Leary Catherine Genestie Cyrus Chargari Philippe Morice S ébastien Gouy Source Type: research

Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health
Bull Cancer. 2021 Oct 7:S0007-4551(21)00308-8. doi: 10.1016/j.bulcan.2021.09.001. Online ahead of print.ABSTRACTSince 2013, the process of pricing of innovative drugs by the French National Health Insurance has considered both cost-effectiveness and budget impact. CAR-T cell therapies were first subject to economic evaluation from 2019 in France. We aim to describe the process and results of the economic evaluation of tisagenlecleucel and axicabtagene ciloleucel as well as the challenges these evaluations raised. Evaluations submitted by the firms were reviewed by HAS and submitted to the Committee of Economic Evaluation a...
Source: Bulletin du Cancer - October 11, 2021 Category: Cancer & Oncology Authors: V éronique Raimond Emmanuelle Kaltenbach Christophe Adam S ébastien Lazzarotto Catherine Le Gal ès Lionel Perrier J érôme Wittwer Source Type: research

Surgical de-escalation in gynecologic oncology
Bull Cancer. 2021 Oct 7:S0007-4551(21)00358-1. doi: 10.1016/j.bulcan.2021.06.012. Online ahead of print.ABSTRACTThe evolution of knowledge in gynecologic oncology is leading to surgical de-escalation in several areas, particularly in lymph node staging. Sentinel lymph node biopsy that was initially used in low and intermediate risk endometrial cancer, has now been extended to high-intermediate and high-risk endometrial cancer. Sentinel lymph node biopsy plays also an important role in the nodal staging of early-stage cervical cancer. The radicality of hysterectomies in patients with early cervical cancer is under debate. S...
Source: Bulletin du Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Fran çois Zaccarini Claire Sanson Amandine Maulard St éphanie Scherier Patricia Pautier Alexandra Leary Catherine Genestie Cyrus Chargari Philippe Morice S ébastien Gouy Source Type: research

Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health
Bull Cancer. 2021 Oct 7:S0007-4551(21)00308-8. doi: 10.1016/j.bulcan.2021.09.001. Online ahead of print.ABSTRACTSince 2013, the process of pricing of innovative drugs by the French National Health Insurance has considered both cost-effectiveness and budget impact. CAR-T cell therapies were first subject to economic evaluation from 2019 in France. We aim to describe the process and results of the economic evaluation of tisagenlecleucel and axicabtagene ciloleucel as well as the challenges these evaluations raised. Evaluations submitted by the firms were reviewed by HAS and submitted to the Committee of Economic Evaluation a...
Source: Bulletin du Cancer - October 11, 2021 Category: Cancer & Oncology Authors: V éronique Raimond Emmanuelle Kaltenbach Christophe Adam S ébastien Lazzarotto Catherine Le Gal ès Lionel Perrier J érôme Wittwer Source Type: research

Surgical de-escalation in gynecologic oncology
Bull Cancer. 2021 Oct 7:S0007-4551(21)00358-1. doi: 10.1016/j.bulcan.2021.06.012. Online ahead of print.ABSTRACTThe evolution of knowledge in gynecologic oncology is leading to surgical de-escalation in several areas, particularly in lymph node staging. Sentinel lymph node biopsy that was initially used in low and intermediate risk endometrial cancer, has now been extended to high-intermediate and high-risk endometrial cancer. Sentinel lymph node biopsy plays also an important role in the nodal staging of early-stage cervical cancer. The radicality of hysterectomies in patients with early cervical cancer is under debate. S...
Source: Bulletin du Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Fran çois Zaccarini Claire Sanson Amandine Maulard St éphanie Scherier Patricia Pautier Alexandra Leary Catherine Genestie Cyrus Chargari Philippe Morice S ébastien Gouy Source Type: research

Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health
Bull Cancer. 2021 Oct 7:S0007-4551(21)00308-8. doi: 10.1016/j.bulcan.2021.09.001. Online ahead of print.ABSTRACTSince 2013, the process of pricing of innovative drugs by the French National Health Insurance has considered both cost-effectiveness and budget impact. CAR-T cell therapies were first subject to economic evaluation from 2019 in France. We aim to describe the process and results of the economic evaluation of tisagenlecleucel and axicabtagene ciloleucel as well as the challenges these evaluations raised. Evaluations submitted by the firms were reviewed by HAS and submitted to the Committee of Economic Evaluation a...
Source: Bulletin du Cancer - October 11, 2021 Category: Cancer & Oncology Authors: V éronique Raimond Emmanuelle Kaltenbach Christophe Adam S ébastien Lazzarotto Catherine Le Gal ès Lionel Perrier J érôme Wittwer Source Type: research

Surgical de-escalation in gynecologic oncology
Bull Cancer. 2021 Oct 7:S0007-4551(21)00358-1. doi: 10.1016/j.bulcan.2021.06.012. Online ahead of print.ABSTRACTThe evolution of knowledge in gynecologic oncology is leading to surgical de-escalation in several areas, particularly in lymph node staging. Sentinel lymph node biopsy that was initially used in low and intermediate risk endometrial cancer, has now been extended to high-intermediate and high-risk endometrial cancer. Sentinel lymph node biopsy plays also an important role in the nodal staging of early-stage cervical cancer. The radicality of hysterectomies in patients with early cervical cancer is under debate. S...
Source: Bulletin du Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Fran çois Zaccarini Claire Sanson Amandine Maulard St éphanie Scherier Patricia Pautier Alexandra Leary Catherine Genestie Cyrus Chargari Philippe Morice S ébastien Gouy Source Type: research

Start of activity with the MRIdian ® system: The first 200 patients treated at the Institut Paoli-Calmettes
We report in this article our early experience.METHODS: Data related to patients treated on the MRIdian® (Viewray®) were prospectively collected. Procedures concerning the implementation of the system and internal organizational issues were summarized.RESULTS: Between February 2019 and March 2020, 201 patients were treated: 40% of treatments were normofractionated (n=70) and 60% used hypofractionation (n=105). The reported monthly occupancy rate at one, six and twelve months was 30%, 62%, and 90%. The distribution of normofractionated treatments was dominated by prostatic (29%) and pancreatic (26%) cancers, followe...
Source: Bulletin du Cancer - October 9, 2021 Category: Cancer & Oncology Authors: Marguerite Tyran Pierre Fau Hugues Mailleux Pierre Eustache Mohamed Benkreira Naji Salem V éronique Favrel Laurence Gonzague Laurence Moureau-Zabotto Leonel Varela Pierre Annede Agnes Tallet Source Type: research

Start of activity with the MRIdian ® system: The first 200 patients treated at the Institut Paoli-Calmettes
We report in this article our early experience.METHODS: Data related to patients treated on the MRIdian® (Viewray®) were prospectively collected. Procedures concerning the implementation of the system and internal organizational issues were summarized.RESULTS: Between February 2019 and March 2020, 201 patients were treated: 40% of treatments were normofractionated (n=70) and 60% used hypofractionation (n=105). The reported monthly occupancy rate at one, six and twelve months was 30%, 62%, and 90%. The distribution of normofractionated treatments was dominated by prostatic (29%) and pancreatic (26%) cancers, followe...
Source: Bulletin du Cancer - October 9, 2021 Category: Cancer & Oncology Authors: Marguerite Tyran Pierre Fau Hugues Mailleux Pierre Eustache Mohamed Benkreira Naji Salem V éronique Favrel Laurence Gonzague Laurence Moureau-Zabotto Leonel Varela Pierre Annede Agnes Tallet Source Type: research

De-escalation strategy in surgical oncology
Bull Cancer. 2021 Oct 4:S0007-4551(21)00359-3. doi: 10.1016/j.bulcan.2021.06.013. Online ahead of print.NO ABSTRACTPMID:34620495 | DOI:10.1016/j.bulcan.2021.06.013 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 8, 2021 Category: Cancer & Oncology Authors: Serge Evrard Source Type: research

De-escalation strategy in surgical oncology
Bull Cancer. 2021 Oct 4:S0007-4551(21)00359-3. doi: 10.1016/j.bulcan.2021.06.013. Online ahead of print.NO ABSTRACTPMID:34620495 | DOI:10.1016/j.bulcan.2021.06.013 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 8, 2021 Category: Cancer & Oncology Authors: Serge Evrard Source Type: research

New European approval: Duvelisib  - relapsed/refractory CLL and follicular lymphoma
Bull Cancer. 2021 Oct 1:S0007-4551(21)00309-X. doi: 10.1016/j.bulcan.2021.06.010. Online ahead of print.NO ABSTRACTPMID:34607678 | DOI:10.1016/j.bulcan.2021.06.010 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 5, 2021 Category: Cancer & Oncology Authors: L éa Fornero Sylvain Lamure Source Type: research

New European approval: Duvelisib  - relapsed/refractory CLL and follicular lymphoma
Bull Cancer. 2021 Oct 1:S0007-4551(21)00309-X. doi: 10.1016/j.bulcan.2021.06.010. Online ahead of print.NO ABSTRACTPMID:34607678 | DOI:10.1016/j.bulcan.2021.06.010 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 5, 2021 Category: Cancer & Oncology Authors: L éa Fornero Sylvain Lamure Source Type: research

New European approval: Duvelisib  - relapsed/refractory CLL and follicular lymphoma
Bull Cancer. 2021 Oct 1:S0007-4551(21)00309-X. doi: 10.1016/j.bulcan.2021.06.010. Online ahead of print.NO ABSTRACTPMID:34607678 | DOI:10.1016/j.bulcan.2021.06.010 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 5, 2021 Category: Cancer & Oncology Authors: L éa Fornero Sylvain Lamure Source Type: research

Drug approval: Selpercatinib and pralsetinib  - RET-altered thyroid cancer
Bull Cancer. 2021 Sep 28:S0007-4551(21)00301-5. doi: 10.1016/j.bulcan.2021.05.009. Online ahead of print.NO ABSTRACTPMID:34598787 | DOI:10.1016/j.bulcan.2021.05.009 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 2, 2021 Category: Cancer & Oncology Authors: Baudouin Courtier Julien Hadoux Source Type: research

Atezolizumab in a first-line setting in non-small-cell lung cancer with high PD-L1  expression
Bull Cancer. 2021 Sep 28:S0007-4551(21)00310-6. doi: 10.1016/j.bulcan.2021.06.011. Online ahead of print.NO ABSTRACTPMID:34598788 | DOI:10.1016/j.bulcan.2021.06.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 2, 2021 Category: Cancer & Oncology Authors: Matthieu Roulleaux Dugage Solenn Brosseau Source Type: research

Drug approval: Selpercatinib and pralsetinib  - RET-altered thyroid cancer
Bull Cancer. 2021 Sep 28:S0007-4551(21)00301-5. doi: 10.1016/j.bulcan.2021.05.009. Online ahead of print.NO ABSTRACTPMID:34598787 | DOI:10.1016/j.bulcan.2021.05.009 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 2, 2021 Category: Cancer & Oncology Authors: Baudouin Courtier Julien Hadoux Source Type: research

Atezolizumab in a first-line setting in non-small-cell lung cancer with high PD-L1  expression
Bull Cancer. 2021 Sep 28:S0007-4551(21)00310-6. doi: 10.1016/j.bulcan.2021.06.011. Online ahead of print.NO ABSTRACTPMID:34598788 | DOI:10.1016/j.bulcan.2021.06.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 2, 2021 Category: Cancer & Oncology Authors: Matthieu Roulleaux Dugage Solenn Brosseau Source Type: research

Drug approval: Selpercatinib and pralsetinib  - RET-altered thyroid cancer
Bull Cancer. 2021 Sep 28:S0007-4551(21)00301-5. doi: 10.1016/j.bulcan.2021.05.009. Online ahead of print.NO ABSTRACTPMID:34598787 | DOI:10.1016/j.bulcan.2021.05.009 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 2, 2021 Category: Cancer & Oncology Authors: Baudouin Courtier Julien Hadoux Source Type: research

Atezolizumab in a first-line setting in non-small-cell lung cancer with high PD-L1  expression
Bull Cancer. 2021 Sep 28:S0007-4551(21)00310-6. doi: 10.1016/j.bulcan.2021.06.011. Online ahead of print.NO ABSTRACTPMID:34598788 | DOI:10.1016/j.bulcan.2021.06.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 2, 2021 Category: Cancer & Oncology Authors: Matthieu Roulleaux Dugage Solenn Brosseau Source Type: research

Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network
Bull Cancer. 2021 Sep 27:S0007-4551(21)00303-9. doi: 10.1016/j.bulcan.2021.06.009. Online ahead of print.ABSTRACTRefractory thyroid cancers include radio-iodine-refractory cancers, metastatic or locally advanced unresectable medullary and anaplastic thyroid cancers. Their management has been based for several years on the use of multi-target kinase inhibitors, with anti-angiogenic action, with the exception of anaplastic cancers usually treated with chemo- and radiotherapy. The situation has recently evolved due to the availability of molecular genotyping techniques allowing the discovery of rare but targetable molecular a...
Source: Bulletin du Cancer - October 1, 2021 Category: Cancer & Oncology Authors: Christelle de la Fouchardi ère Johanna Wassermann Fabien Calcagno St éphane Bardet Abir Al Ghuzlan Isabelle Borget Fran çoise Borson Chazot Christine Do Cao Camille Buffet Slimane Zerdoud Myriam Decaussin-Petrucci Yann Godbert Sophie Leboulleux Source Type: research

Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network
Bull Cancer. 2021 Sep 27:S0007-4551(21)00303-9. doi: 10.1016/j.bulcan.2021.06.009. Online ahead of print.ABSTRACTRefractory thyroid cancers include radio-iodine-refractory cancers, metastatic or locally advanced unresectable medullary and anaplastic thyroid cancers. Their management has been based for several years on the use of multi-target kinase inhibitors, with anti-angiogenic action, with the exception of anaplastic cancers usually treated with chemo- and radiotherapy. The situation has recently evolved due to the availability of molecular genotyping techniques allowing the discovery of rare but targetable molecular a...
Source: Bulletin du Cancer - October 1, 2021 Category: Cancer & Oncology Authors: Christelle de la Fouchardi ère Johanna Wassermann Fabien Calcagno St éphane Bardet Abir Al Ghuzlan Isabelle Borget Fran çoise Borson Chazot Christine Do Cao Camille Buffet Slimane Zerdoud Myriam Decaussin-Petrucci Yann Godbert Sophie Leboulleux Source Type: research

Antalgic effects of socio-aesthetics in cancer patients
Bull Cancer. 2021 Sep 24:S0007-4551(21)00306-4. doi: 10.1016/j.bulcan.2021.05.012. Online ahead of print.ABSTRACTINTRODUCTION: Socio-aesthetics is the delivery appropriate beauty care in a population weakened by a physical, psychological and/or social attack. It has found its place in indications in both medical (especially in oncology) and social settings. It offers many types of treatments including facials, foot beauty, make-up, wig tips, body massage, product advice, cosmetic manicure, varnishing… The main purpose of this study was to evaluate pain reduction as a result of socio-aesthetics.METHODS: One hundred a...
Source: Bulletin du Cancer - September 28, 2021 Category: Cancer & Oncology Authors: Guillaume Buiret Sarah Sandonato Fr édéric Chidiac Sophie Lantheaume Source Type: research

Antalgic effects of socio-aesthetics in cancer patients
Bull Cancer. 2021 Sep 24:S0007-4551(21)00306-4. doi: 10.1016/j.bulcan.2021.05.012. Online ahead of print.ABSTRACTINTRODUCTION: Socio-aesthetics is the delivery appropriate beauty care in a population weakened by a physical, psychological and/or social attack. It has found its place in indications in both medical (especially in oncology) and social settings. It offers many types of treatments including facials, foot beauty, make-up, wig tips, body massage, product advice, cosmetic manicure, varnishing… The main purpose of this study was to evaluate pain reduction as a result of socio-aesthetics.METHODS: One hundred a...
Source: Bulletin du Cancer - September 28, 2021 Category: Cancer & Oncology Authors: Guillaume Buiret Sarah Sandonato Fr édéric Chidiac Sophie Lantheaume Source Type: research

Antalgic effects of socio-aesthetics in cancer patients
Bull Cancer. 2021 Sep 24:S0007-4551(21)00306-4. doi: 10.1016/j.bulcan.2021.05.012. Online ahead of print.ABSTRACTINTRODUCTION: Socio-aesthetics is the delivery appropriate beauty care in a population weakened by a physical, psychological and/or social attack. It has found its place in indications in both medical (especially in oncology) and social settings. It offers many types of treatments including facials, foot beauty, make-up, wig tips, body massage, product advice, cosmetic manicure, varnishing… The main purpose of this study was to evaluate pain reduction as a result of socio-aesthetics.METHODS: One hundred a...
Source: Bulletin du Cancer - September 28, 2021 Category: Cancer & Oncology Authors: Guillaume Buiret Sarah Sandonato Fr édéric Chidiac Sophie Lantheaume Source Type: research

Interest of the bc-GenExMiner web tool in oncology
Bull Cancer. 2021 Sep 21:S0007-4551(21)00299-X. doi: 10.1016/j.bulcan.2021.05.008. Online ahead of print.ABSTRACTWe are taking advantage of the launch of the latest version (v4.6) of our web-based data mining tool "breast cancer gene-expression miner" (bc-GenExMiner) to take stock of its position within the oncology research landscape and to present an activity report ten years after its establishment (http://bcgenex.ico.unicancer.fr). bc-GenExMiner is an open-access, user-friendly tool for statistical mining on breast tumor transcriptomes, annotated with more than 20 clinicopathologic and molecular characteristi...
Source: Bulletin du Cancer - September 25, 2021 Category: Cancer & Oncology Authors: Pascal J ézéquel Wilfried Gouraud Fadoua Ben Azzouz Agn ès Basseville Philippe P Juin Hamza Lasla Mario Campone Source Type: research

Very old patients in multidisciplinary team meeting in PACA: a one-year survey
Bull Cancer. 2021 Sep 21:S0007-4551(21)00305-2. doi: 10.1016/j.bulcan.2021.05.011. Online ahead of print.ABSTRACTINTRODUCTION: In 2011, 11% of all cancers were diagnosed in people over 85 years old. With the current aging of the French population associated with health progress, we will be confronted more and more frequently with the treatment of very old patients, and this until the horizon 2050, when the population over 75 years old will represent approximately 15% of the total French population (compared to 9.1% in 2015).METHODS: To understand the management methods for patients over 85 years old with cancer, we carried...
Source: Bulletin du Cancer - September 25, 2021 Category: Cancer & Oncology Authors: Emilien Billon Louis Tassy Oph élie Boulogne Maud Cecile C écile Braticevic Mich èle Pibarot Fr édérique Rousseau Source Type: research

How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
This study aims to assess the cost of the hospital stay for the administration of anti-CD19 CAR-T cells in France. Data were collected from the French Medical Information Systems Program (PMSI) and all hospital stays associated with an administrated drug encoded 9439938 (tisagenlecleucel, Kymriah®) or 9440456 (axicabtagene ciloleucel, Yescarta®) between January 2019 and December 2020 were included. 485 hospital stays associated with an injection of anti-CD19 CAR-T cells were identified, of which 44 (9%), 139 (28.7%), and 302 (62.3%) were for tisagenlecleucel in acute lymphoblastic leukaemia (ALL), tisagenlecleucel ...
Source: Bulletin du Cancer - September 25, 2021 Category: Cancer & Oncology Authors: Marius Huguet V éronique Raimond Emmanuelle Kaltenbach Vincent Augusto Lionel Perrier Source Type: research

Interest of the bc-GenExMiner web tool in oncology
Bull Cancer. 2021 Sep 21:S0007-4551(21)00299-X. doi: 10.1016/j.bulcan.2021.05.008. Online ahead of print.ABSTRACTWe are taking advantage of the launch of the latest version (v4.6) of our web-based data mining tool "breast cancer gene-expression miner" (bc-GenExMiner) to take stock of its position within the oncology research landscape and to present an activity report ten years after its establishment (http://bcgenex.ico.unicancer.fr). bc-GenExMiner is an open-access, user-friendly tool for statistical mining on breast tumor transcriptomes, annotated with more than 20 clinicopathologic and molecular characteristi...
Source: Bulletin du Cancer - September 25, 2021 Category: Cancer & Oncology Authors: Pascal J ézéquel Wilfried Gouraud Fadoua Ben Azzouz Agn ès Basseville Philippe P Juin Hamza Lasla Mario Campone Source Type: research

Very old patients in multidisciplinary team meeting in PACA: a one-year survey
Bull Cancer. 2021 Sep 21:S0007-4551(21)00305-2. doi: 10.1016/j.bulcan.2021.05.011. Online ahead of print.ABSTRACTINTRODUCTION: In 2011, 11% of all cancers were diagnosed in people over 85 years old. With the current aging of the French population associated with health progress, we will be confronted more and more frequently with the treatment of very old patients, and this until the horizon 2050, when the population over 75 years old will represent approximately 15% of the total French population (compared to 9.1% in 2015).METHODS: To understand the management methods for patients over 85 years old with cancer, we carried...
Source: Bulletin du Cancer - September 25, 2021 Category: Cancer & Oncology Authors: Emilien Billon Louis Tassy Oph élie Boulogne Maud Cecile C écile Braticevic Mich èle Pibarot Fr édérique Rousseau Source Type: research

How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
This study aims to assess the cost of the hospital stay for the administration of anti-CD19 CAR-T cells in France. Data were collected from the French Medical Information Systems Program (PMSI) and all hospital stays associated with an administrated drug encoded 9439938 (tisagenlecleucel, Kymriah®) or 9440456 (axicabtagene ciloleucel, Yescarta®) between January 2019 and December 2020 were included. 485 hospital stays associated with an injection of anti-CD19 CAR-T cells were identified, of which 44 (9%), 139 (28.7%), and 302 (62.3%) were for tisagenlecleucel in acute lymphoblastic leukaemia (ALL), tisagenlecleucel ...
Source: Bulletin du Cancer - September 25, 2021 Category: Cancer & Oncology Authors: Marius Huguet V éronique Raimond Emmanuelle Kaltenbach Vincent Augusto Lionel Perrier Source Type: research

Interest of the bc-GenExMiner web tool in oncology
Bull Cancer. 2021 Sep 21:S0007-4551(21)00299-X. doi: 10.1016/j.bulcan.2021.05.008. Online ahead of print.ABSTRACTWe are taking advantage of the launch of the latest version (v4.6) of our web-based data mining tool "breast cancer gene-expression miner" (bc-GenExMiner) to take stock of its position within the oncology research landscape and to present an activity report ten years after its establishment (http://bcgenex.ico.unicancer.fr). bc-GenExMiner is an open-access, user-friendly tool for statistical mining on breast tumor transcriptomes, annotated with more than 20 clinicopathologic and molecular characteristi...
Source: Bulletin du Cancer - September 25, 2021 Category: Cancer & Oncology Authors: Pascal J ézéquel Wilfried Gouraud Fadoua Ben Azzouz Agn ès Basseville Philippe P Juin Hamza Lasla Mario Campone Source Type: research

Very old patients in multidisciplinary team meeting in PACA: a one-year survey
Bull Cancer. 2021 Sep 21:S0007-4551(21)00305-2. doi: 10.1016/j.bulcan.2021.05.011. Online ahead of print.ABSTRACTINTRODUCTION: In 2011, 11% of all cancers were diagnosed in people over 85 years old. With the current aging of the French population associated with health progress, we will be confronted more and more frequently with the treatment of very old patients, and this until the horizon 2050, when the population over 75 years old will represent approximately 15% of the total French population (compared to 9.1% in 2015).METHODS: To understand the management methods for patients over 85 years old with cancer, we carried...
Source: Bulletin du Cancer - September 25, 2021 Category: Cancer & Oncology Authors: Emilien Billon Louis Tassy Oph élie Boulogne Maud Cecile C écile Braticevic Mich èle Pibarot Fr édérique Rousseau Source Type: research

How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
This study aims to assess the cost of the hospital stay for the administration of anti-CD19 CAR-T cells in France. Data were collected from the French Medical Information Systems Program (PMSI) and all hospital stays associated with an administrated drug encoded 9439938 (tisagenlecleucel, Kymriah®) or 9440456 (axicabtagene ciloleucel, Yescarta®) between January 2019 and December 2020 were included. 485 hospital stays associated with an injection of anti-CD19 CAR-T cells were identified, of which 44 (9%), 139 (28.7%), and 302 (62.3%) were for tisagenlecleucel in acute lymphoblastic leukaemia (ALL), tisagenlecleucel ...
Source: Bulletin du Cancer - September 25, 2021 Category: Cancer & Oncology Authors: Marius Huguet V éronique Raimond Emmanuelle Kaltenbach Vincent Augusto Lionel Perrier Source Type: research

Prophylactic mastectomy and occult cancer: a ten-year experience at a cancer center
DISCUSSION: Prophylactic mastectomy is the only effective preventive action against breast cancer. Women must be clearly informed of possible complications, high reoperation rate and potential pathological findings. Identifying women most at risk for breast cancer would help to better target those who will benefit most from surgery.PMID:34556291 | DOI:10.1016/j.bulcan.2021.05.007 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 24, 2021 Category: Cancer & Oncology Authors: Manon Mangiardi-Veltin Foucauld Chamming's Anne Jaffre Aur élien Rousvoal Christine Tunon de Lara V éronique Brouste St éphanie Hoppe Claire S énéchal Source Type: research

Surgical de-escalation for head and neck cancer surgery
Bull Cancer. 2021 Sep 20:S0007-4551(21)00302-7. doi: 10.1016/j.bulcan.2021.06.008. Online ahead of print.ABSTRACTHead and neck cancer surgery often has functional and aesthetic consequences. De-escalation surgery is a major concern for surgeons with a constant desire to develop surgical techniques with less invasive approaches and to preserve anatomical structures as much as possible. This was made possible by the appearance of minimally transoral and endonasal surgery as well as by the limitation of the surgical procedure by neoadjuvant treatments or by the limitation of surgical excision without compromising the oncologi...
Source: Bulletin du Cancer - September 24, 2021 Category: Cancer & Oncology Authors: Emilie Beulque Sophie Cortese Romina Mastronicola Gilles Dolivet Source Type: research

Establishing at a shared and common educational assessment at Curie Institute
Bull Cancer. 2021 Sep 20:S0007-4551(21)00296-4. doi: 10.1016/j.bulcan.2021.04.023. Online ahead of print.ABSTRACTThe Institut Curie initiated a therapeutic patient education activity in 2011 by creating several programs. Coordinated and animated by different multidisciplinary teams, these functioned autonomously, with a different initial educational assessment for each one. This organization broke up the patient's educational pathway, and the educational offer, which sometimes proved to be redundant, most often corresponding to the needs shared by all cancer patients. The transversal therapeutic education unit allowed the ...
Source: Bulletin du Cancer - September 24, 2021 Category: Cancer & Oncology Authors: Carole Kalog éropoulos Sil ène Delorme Claire Llambrich-Molines Nicolas Girard Evelyne Renault-Tessier Source Type: research

Academic carriers in oncology and radiotherapy: Update for the readers of Bulletin du Cancer
Bull Cancer. 2021 Sep 20:S0007-4551(21)00287-3. doi: 10.1016/j.bulcan.2021.08.005. Online ahead of print.NO ABSTRACTPMID:34556294 | DOI:10.1016/j.bulcan.2021.08.005 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 24, 2021 Category: Cancer & Oncology Authors: Gilles Calais Jean-Marc Classe Michel Ducreux Christophe Hennequin Florence Joly Lucie Karayan-Tapon Delphine Antoni Olivier Capitain Jocelyn C éraline Julien P éron Emeline Tabouret Antoine Thiery-Vuillemin Source Type: research

Surgical oncologists an "endangered species"
Bull Cancer. 2021 Sep 20:S0007-4551(21)00295-2. doi: 10.1016/j.bulcan.2021.05.006. Online ahead of print.NO ABSTRACTPMID:34556295 | DOI:10.1016/j.bulcan.2021.05.006 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 24, 2021 Category: Cancer & Oncology Authors: Emmanuel Barranger Charles Coutant Philippe Marre R émy Salmon Source Type: research

Prophylactic mastectomy and occult cancer: a ten-year experience at a cancer center
DISCUSSION: Prophylactic mastectomy is the only effective preventive action against breast cancer. Women must be clearly informed of possible complications, high reoperation rate and potential pathological findings. Identifying women most at risk for breast cancer would help to better target those who will benefit most from surgery.PMID:34556291 | DOI:10.1016/j.bulcan.2021.05.007 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 24, 2021 Category: Cancer & Oncology Authors: Manon Mangiardi-Veltin Foucauld Chamming's Anne Jaffre Aur élien Rousvoal Christine Tunon de Lara V éronique Brouste St éphanie Hoppe Claire S énéchal Source Type: research

Surgical de-escalation for head and neck cancer surgery
Bull Cancer. 2021 Sep 20:S0007-4551(21)00302-7. doi: 10.1016/j.bulcan.2021.06.008. Online ahead of print.ABSTRACTHead and neck cancer surgery often has functional and aesthetic consequences. De-escalation surgery is a major concern for surgeons with a constant desire to develop surgical techniques with less invasive approaches and to preserve anatomical structures as much as possible. This was made possible by the appearance of minimally transoral and endonasal surgery as well as by the limitation of the surgical procedure by neoadjuvant treatments or by the limitation of surgical excision without compromising the oncologi...
Source: Bulletin du Cancer - September 24, 2021 Category: Cancer & Oncology Authors: Emilie Beulque Sophie Cortese Romina Mastronicola Gilles Dolivet Source Type: research

Establishing at a shared and common educational assessment at Curie Institute
Bull Cancer. 2021 Sep 20:S0007-4551(21)00296-4. doi: 10.1016/j.bulcan.2021.04.023. Online ahead of print.ABSTRACTThe Institut Curie initiated a therapeutic patient education activity in 2011 by creating several programs. Coordinated and animated by different multidisciplinary teams, these functioned autonomously, with a different initial educational assessment for each one. This organization broke up the patient's educational pathway, and the educational offer, which sometimes proved to be redundant, most often corresponding to the needs shared by all cancer patients. The transversal therapeutic education unit allowed the ...
Source: Bulletin du Cancer - September 24, 2021 Category: Cancer & Oncology Authors: Carole Kalog éropoulos Sil ène Delorme Claire Llambrich-Molines Nicolas Girard Evelyne Renault-Tessier Source Type: research

Academic carriers in oncology and radiotherapy: Update for the readers of Bulletin du Cancer
Bull Cancer. 2021 Sep 20:S0007-4551(21)00287-3. doi: 10.1016/j.bulcan.2021.08.005. Online ahead of print.NO ABSTRACTPMID:34556294 | DOI:10.1016/j.bulcan.2021.08.005 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 24, 2021 Category: Cancer & Oncology Authors: Gilles Calais Jean-Marc Classe Michel Ducreux Christophe Hennequin Florence Joly Lucie Karayan-Tapon Delphine Antoni Olivier Capitain Jocelyn C éraline Julien P éron Emeline Tabouret Antoine Thiery-Vuillemin Source Type: research

Surgical oncologists an "endangered species"
Bull Cancer. 2021 Sep 20:S0007-4551(21)00295-2. doi: 10.1016/j.bulcan.2021.05.006. Online ahead of print.NO ABSTRACTPMID:34556295 | DOI:10.1016/j.bulcan.2021.05.006 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 24, 2021 Category: Cancer & Oncology Authors: Emmanuel Barranger Charles Coutant Philippe Marre R émy Salmon Source Type: research

New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma
Bull Cancer. 2021 Sep 16:S0007-4551(21)00294-0. doi: 10.1016/j.bulcan.2021.05.005. Online ahead of print.NO ABSTRACTPMID:34538614 | DOI:10.1016/j.bulcan.2021.05.005 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Natacha Naoun Yann-Alexandre Vano Source Type: research

New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma
Bull Cancer. 2021 Sep 16:S0007-4551(21)00294-0. doi: 10.1016/j.bulcan.2021.05.005. Online ahead of print.NO ABSTRACTPMID:34538614 | DOI:10.1016/j.bulcan.2021.05.005 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Natacha Naoun Yann-Alexandre Vano Source Type: research

New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma
Bull Cancer. 2021 Sep 16:S0007-4551(21)00294-0. doi: 10.1016/j.bulcan.2021.05.005. Online ahead of print.NO ABSTRACTPMID:34538614 | DOI:10.1016/j.bulcan.2021.05.005 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Natacha Naoun Yann-Alexandre Vano Source Type: research

Do people living with HIV face more secondary cancers than general population: From the French CANCERVIH network
DISCUSSION: With the aging of PLWHIV, the incidence of second and subsequent cancers is expected to increase in this population. Immuno-virological control should be maintained. Increased surveillance, early prevention and screening programs should be offered to all PLWHIV, including those with an undetectable HIV viral load and/or immune restoration.PMID:34452700 | DOI:10.1016/j.bulcan.2021.01.026 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 28, 2021 Category: Cancer & Oncology Authors: Marianne Veyri Armelle Lavol é Sylvain Choquet Dominique Costagliola Caroline Solas Christine Katlama Isabelle Poizot-Martin Jean-Philippe Spano Source Type: research